Provided by Tiger Trade Technology Pte. Ltd.

FUSEN PHARM

1.240
+0.14012.73%
Volume:596.00K
Turnover:713.00K
Market Cap:916.36M
PE:-4.86
High:1.300
Open:1.090
Low:1.080
Close:1.100
52wk High:1.750
52wk Low:0.235
Shares:739.00M
HK Float Shares:739.00M
Volume Ratio:0.60
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.255
ROE:-40.49%
ROA:-2.47%
PB:2.34
PE(LYR):-4.86
PS:3.36

Loading ...

FUSEN PHARM (01652) Sets 31 March 2026 Board Meeting to Approve FY 2025 Results and Evaluate Final Dividend

Bulletin Express
·
Mar 19

Fusen Pharmaceutical Company Limited's (HKG:1652) Business Is Yet to Catch Up With Its Share Price

Simply Wall St.
·
Feb 13

Fusen Pharmaceutical (01652) Announces Monthly Return for January 2026

Bulletin Express
·
Feb 03

BRIEF-Fusen Pharmaceutical Obtains Approval For Marketing From NMPA As Phosphate Supplement

Reuters
·
Dec 29, 2025

Fusen Pharmaceutical - Obtained Approval for Marketing From National Medical Products Administration of the PRC as Phosphate Supplement.

THOMSON REUTERS
·
Dec 29, 2025

Fusen Pharmaceutical Wins Approval for Compound Potassium Hydrogen Phosphate Injection

Reuters
·
Dec 29, 2025

FUSEN PHARM (01652) Appoints Zhongzheng Tianheng as New Auditor

Stock News
·
Dec 24, 2025

Fusen Pharmaceutical Replaces Auditor After Fee Dispute

Reuters
·
Dec 24, 2025

FUSEN PHARM (01652): "Nicardipine Hydrochloride Injection" Generic Drug Application Approved for Market Launch

Stock News
·
Dec 12, 2025

Fusen Pharmaceutical - Approval Issued by Nmpa for Consistency Evaluation of Nicardipine Hydrochloride Injection

THOMSON REUTERS
·
Dec 12, 2025

Fusen Pharmaceutical Wins Regulatory Approval for Nicardipine Hydrochloride Injection in China

Reuters
·
Dec 12, 2025

Fusen Pharmaceutical (01652) Releases Monthly Return for November 2025

Bulletin Express
·
Dec 01, 2025

HK Stock Movement | FUSEN PHARM (01652) Surges Over 7% as Its "Azilsartan Potassium Tablets" Gain Market Approval

Stock News
·
Nov 17, 2025

Fusen Pharmaceutical's Unit Get China Nod for Marketing of Hypertension Drug

MT Newswires Live
·
Nov 14, 2025

Fusen Pharmaceutical - Approval From Nmpa

THOMSON REUTERS
·
Nov 14, 2025

Fusen Pharmaceutical Co Ltd - Measartan Potassium Tablets Approved for Marketing

THOMSON REUTERS
·
Nov 14, 2025

Further weakness as Fusen Pharmaceutical (HKG:1652) drops 12% this week, taking five-year losses to 85%

Simply Wall St.
·
Nov 09, 2025

Fusen Pharmaceutical (01652) Reports October 2025 Monthly Securities Movements

Bulletin Express
·
Nov 03, 2025

HK Stock Movement | FUSEN PHARM (01652) Surges Nearly 74% Intraday as Enzalutamide Soft Capsule Approved and Metformin Empagliflozin Tablet Included in National Bulk-Buy Program

Stock News
·
Oct 31, 2025

FUSEN PHARM (01652): "Enzalutamide Soft Capsule" Approved for Market Launch

Stock News
·
Oct 30, 2025